Clinical Trial

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-21; most recent amendment 2025-09-26.
Status change: Recruiting → Active, Not Recruiting 2025-09-26
Status change: Active, Not Recruiting → Recruiting 2025-07-31
Status change: Recruiting → Active, Not Recruiting 2025-07-14
Trial Details
NCT Number NCT06899802
Lead Sponsor Bavarian Nordic
Collaborators: JPM CBRN Medical
Conditions Encephalitis
Enrollment 411 participants
Start Date 2025-03-10
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-10-01